Cyclopentolate/ Phenylephrine

Registered South African indications:

• Mydriasis

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Closed angle glaucoma
• Coadministration with monoamine oxidase inhibitors or within 14 days of their use

Cautions

• Pregnancy
• Breastfeeding
• Cardiovascular disease
• Hypertension
• Hyperthyroidism
• Infants
• Children
• Prolonged use
• Extensive ocular surface disease
• May impair ability to drive or operate machinery

Forms avail. in SA and covered in this monograph: opd

Rapid and profound mydriasis

Cyclopentolate/ Phenylephrine
2/10 (mg/ml)

• Ophthalmic (opd): 1 drop into each eye(s), 5-10min before fundoscopy; Max: 3 applications

Paed. forms avail. in SA and covered in this monograph: opd

Rapid and profound mydriasis

Cyclopentolate/ Phenylephrine
2/10 (mg/ml)

• See adult dosage

To minimise absorption in premature and small infants, occlude the nasolacrimal sac for 2-3min after instillation

Pregnancy

• FDA Pregnancy Category C

Breastfeeding

• Caution

Renal Impairment

• No dose adjustment recommended

Hepatic Impairment

• No dose adjustment recommended

Elderly

• No dose adjustment recommended

Drugs in Sport

• Permitted - No warning

Central Nervous System Disorders

• Psychotic reactions 
• Behavioural disturbances

Sensory Disorders

• Increased intraocular pressure
• Disruption of the corneal epithelium
• Photosensitivity

• Guanethidine
• Reserpine
• Methyldopa
• Tricyclic antidepressants
• Monoamine oxidase inhibitors

Ophthalmic examination

Cyclopentolate
Cyclopentolate is an antimuscarinic agent that blocks muscarinic receptors in the ciliary muscles in the eye to prevent cholinergic stimulation and so doing causing mydriasis and cycloplegia. 

Phenylephrine
Phenylephrine is a direct-acting alpha-adrenergic agonist which also acts on the ciliary muscles of the eye to cause mydriasis.

COMBINATION PREPARATIONS

Cyclopentolate/ Phenylephrine

Eye drops (per ml) 2mg/10mg

• Cyclomydril (Alcon) originator